Bayer's April Gauntlet: A Legal and Governance Crucible
13.04.2026 - 22:42:25 | boerse-global.de
The coming weeks present a critical test for Bayer, with a shareholder meeting, a Supreme Court hearing, and quarterly results set to define its near-term trajectory. Amid this confluence of events, at least one analyst has shifted stance on the stock, signaling a potential recalibration of investor sentiment.
DZ Bank analyst Peter Spengler recently upgraded Bayer from "Sell" to "Hold," raising his price target from 42 to 44 euros. His reassessment hinges on a higher valuation multiple for the Crop Science division for 2027 and lower estimates for pension provisions. The bank argues that the proposed $7.25 billion settlement in the King v. Monsanto case has made the glyphosate litigation risks more calculable, allowing the company's operational performance to move into sharper focus. Despite this upgrade, the share price remains under pressure, trading just above 40 euros—roughly 17% below its February peak of 49.17 euros.
The operational outlook faces its own scrutiny. Management has reaffirmed its full-year guidance for 2026, targeting EBITDA before special items of 9.6 to 10.1 billion euros, compared to 9.669 billion euros the previous year. Pharmaceuticals Chief Operating Officer Sebastian Guth told Reuters that potential US tariffs on pharmaceuticals, capped at 15% under an EU-US trade agreement, are already factored into the company's forecasts. However, the financial story is more complex. Bayer anticipates a negative free cash flow for 2026 due to ongoing litigation payouts, even as net financial debt improved to approximately 29.8 billion euros at the end of 2025, an 8.5% year-on-year reduction.
Should investors sell immediately? Or is it worth buying Bayer?
All eyes, however, are fixed on the US Supreme Court. On April 27, the justices will hear oral arguments in Durnell v. Monsanto, a case with profound implications for Bayer's legal future. The core argument is whether the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) preempts state warning-label laws, given that the EPA has not mandated a cancer warning on Roundup labels. A favorable ruling could effectively halt new lawsuits. The court took the case due to a split in lower courts: two appellate courts rejected Bayer's argument, while the Third Circuit Court of Appeals sided with the company. The outcome is highly uncertain, with 18 amicus briefs filed, including submissions from the attorneys general of Texas, Florida, and Ohio opposing Bayer's position. A final decision is expected by June 2026.
Simultaneously, the company is pushing forward with a major settlement. In February 2026, Bayer announced a $7.25 billion agreement in the King v. Monsanto case to resolve current and future non-Hodgkin lymphoma claims. Judge Timothy J. Boyer granted preliminary approval to this settlement in March 2026.
Governance changes are also on the agenda. At the virtual Annual General Meeting on April 24, shareholders will vote on a proposed dividend of 0.11 euros per share, unchanged from the prior year, with payment scheduled for April 29. They will also elect two new supervisory board members. Long-serving members Paul Achleitner and Colleen Goggins are stepping down, with OMV CEO Alfred Stern and former Cargill and Sara Lee executive Marcel Smits nominated as successors. The company cites Stern's leadership experience and expertise in governance and sustainability issues.
The first tangible read on Bayer's operational progress under these pressures will come with the release of its Q1 2026 results on May 12. This report will show whether cost-cutting initiatives and an anticipated upturn in the agricultural business are gaining traction. For Bayer's management, 2027 is viewed as a potential turning point for financial recovery. Whether that outlook holds depends fundamentally on the decisions made in courtrooms and boardrooms over the next several weeks.
Ad
Bayer Stock: New Analysis - 13 April
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Bayers Aktien ein!
Für. Immer. Kostenlos.
